The B-Cell Depletion Arms Race in CNS Autoimmune Trials Has a New Front-Runner — And It Rewrites the Regulatory Playbook
Obinutuzumab β's Phase 3 trial shows 93.1% relapse risk reduction in AQP4+ NMOSD, forcing a rethink of how rare...
Phase 3 Trial Design
Reading the SYNCHRONIZE-MASLD Phase 3 Trial Publication Closely
The SYNCHRONIZE-MASLD Phase 3 trial in Nature Medicine shows survodutide cutting liver fat by 64.3% vs placebo — here's...
The Trial That Should Rewrite the Rare Disease Playbook — But Probably Won’t
AstraZeneca's Phase 3 benralizumab trial in hypereosinophilic syndrome just delivered one of the cleanest efficacy signals in rare disease...